Claims for Patent: 8,530,668

Summary for Patent: 8,530,668

Title:	Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor
Abstract:	An optically active 4-phenylthiazole derivative having a thrombopoietin receptor agonist activity and a pharmaceutical composition containing the present compound as an active ingredient are created, and a platelet production regulating agent which can be orally administered is provided. Disclosed is a pharmaceutical composition containing, as an active ingredient, an optically active compound represented by the formula: ##STR00001## wherein, R.sup.1 is a halogen atom or C1-C3 alkyloxy; R.sup.2 is C1-C8 alkyl; R.sup.3 is C1-C8 alkyl; R.sup.4 and R.sup.5 are each independently a fluorine atom or chlorine atom; R.sup.6 is C1-C3 alkyl or C1-C3 alkyloxy; * indicates that a carbon atom marked with an asterisk is an asymmetric carbon, a pharmaceutically acceptable salt thereof, or a solvate thereof.
Inventor(s):	Takayama; Masami (Osaka, JP), Kurose; Noriyuki (Osaka, JP)
Assignee:	Shionogi & Co., Ltd. (Osaki-Shi, Osaka, JP)
Application Number:	12/671,476
Patent Claims:	1. A crystal of (S)-(E)-3-(2,6-dichloro-4-{4-[3-(1-hexyloxyethyl)-2-methyloxyphenyl]thiaz- ol-2-ylcarbamoyl}phenyl)-2-methylacrylic acid characterized by an X-ray powder diffraction pattern comprising peaks located at 17.8 degree, 21.1 degree, 22.5 degree, 23.3 degree, 24.1 degree, and 24.4 degree two-theta angles. 2. A pharmaceutical composition comprising, as an active ingredient, the crystal as defined in claim 1. 3. The pharmaceutical composition according to claim 2, comprising the active ingredient in an amount effective as a thrombopoietin receptor agonist. 4. The pharmaceutical composition according to claim 2, comprising the active ingredient in an amount effective as the platelet production regulating agent.